Download full-text PDF |
Source |
---|
Cureus
November 2024
Department of Cardiology, Mahavoky Atsimo University Hospital, Mahajanga, MDG.
Introduction Dyslipidemia is a major risk factor for atherosclerosis and is included in the metabolic syndrome. Data on dyslipidemia are still lacking in some parts of Africa. Our objectives were to report the prevalence of dyslipidemia and to describe the lipid profile of patients in a hospital in Madagascar.
View Article and Find Full Text PDFJ Clin Lipidol
October 2024
Department of Cardiovascular Medicine and Hypertension, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Environ Res
December 2024
School of Public Health (Shenzhen), Shenzhen Campus of SunYat-sen University, Shenzhen, 518107, China. Electronic address:
Dyslipidemia is a prevalent metabolic disorder in older adults and has negative effects on cardiovascular health. However, the combined effect of paraben, bisphenol A (BPA), and triclosan (TCS) exposure on dyslipidemia and the underlying mechanisms remain unclear. This cross-sectional study recruited 486 individuals ≥60 years in Shenzhen, China.
View Article and Find Full Text PDFDiabetes Res Clin Pract
May 2024
University Hospital San Giovanni di Dio e Ruggi D'Aragona (Salerno); Department of Medicine, Surgery and Dentistry, University of Salerno (Salerno).
Aims: To evaluate the effect of nutritional therapy on glycemic compensation and key cardio-renal risk markers in patients with diabetes and kidney transplant, on insulin treatment by Multiple Daily Injection (MDI) or Continuous Subcutaneous Insulin Infusion (CSII).
Methods: 34 patients with diabetes on insulin treatment and kidney transplant recipients were enrolled;12 participated in the structured nutritional program (intervention group), 22 patients (control group) did not receive nutritional protocol. Both groups were then divided into subgroups according to the method of insulin administration (MDI and CSII).
Polymers (Basel)
October 2023
Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.
Simvastatin (SIM) is a potent lipid-lowering drug used to control hyper-cholesterolemia and prevent cardiovascular diseases. SIM presents low oral bioavailability (5%) because of its low aqueous solubility. In this work, polyelectrolyte complexes (PEC) are developed with different chitosan (CS) and carboxymethylcellulose (CMC) ratios that will allow for an increase in the SIM dissolution rate (2.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!